Dyspepsia is a common condition in the general population but data are lacking on the benefits of effective acid inhibition with proton pump inhibitors in functional dyspepsia. The results of the large, randomised, double blind clinical trials, BOND and OPERA, the Scandinavian PILOT study, and a follow up study, ENCORE, are reviewed. BOND, OPERA, and PILOT aimed to address the question of whether effective acid inhibition with the proton pump inhibitor omeprazole relieves symptoms in patients with functional dyspepsia. ENCORE followed on from this, addressing the consequences of relieving symptoms in patients with functional dyspepsia once they are off therapy.
- functional dyspepsia
- Helicobacter pylori
- GORD, gastro-oesophageal reflux disease
- GSRS, gastrointestinal symptom rating scale
- ITT, intention to treat
- MBS, most bothersome symptom
- PGWB, psychological general well being
Statistics from Altmetric.com
Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The authors of this paper have received sponsorship for travel and an honorarium from AstraZeneca.
NJ Talley has been a consultant and received research grants fromTAP, Takeda, Ledede, Pharmacia, and Janssen
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.